Cutaneous Biology Research Center


Fisher Lab

Our group studies cell death/proliferation signals in relation to development and disease, particularly in cancer of pigment cells (melanoma) and tumors of childhood. We attempt to understand critical modes of cell homeostasis with a goal of molecular targeted therapy as well as prevention of melanoma and other human cancers

Lesions for Malignancy from Normal Development

We study biology of melanocytes as a means of identifying pathways which drive melanoma in man. This includes examination of mechanisms underlying growth/survival of benign moles, most of which contain mutations in either BRAF or N-Ras oncogenes. We also study melanocyte death in hair follicles, a process associated with hair graying. Pathways were identified which link graying to melanocyte and melanoma survival, offering potential leads for novel therapies. Other studies focus on pathways modulating melanocytic responses to environmental cues and employ oncogene-transformed melanocytic lines which exhibit growth factor independence, mimicking human melanoma in a genetically controlled manner.

Control of Life and Death in Melanoma

Malignant transformation of melanocytes produces one of the most treatment resistant malignancies in man. We have identified a transcriptional network which regulates melanoma cell survival and proliferation as well as melanocyte differentiation during development. Using diverse methods including mouse models, human tumor expression arrays and cellular assays, we examine mechanisms through which melanoma cells evade death, with the goal of improving therapy. Studies include preclinical and clinical analyses of novel melanoma treatments. We also study the role of UV in pigmentation responses and carcinogenesis, since this potentially offers novel approaches to skin cancer prevention.

MITF Transcription Factor Family In Development and Cancer

Mitf is a helix-loop-helix factor homologous to Myc, whose mutation in man produces absence of melanocytes. MITF acts as a master regulator of melanocyte development and is targeted by several critical signaling pathways. Recently, members of the Mitf family have been discovered as oncogenes in a variety of human malignancies, particularly sarcomas of childhood. Their roles in cancer as well as strategies to target them therapeutically are under active investigation. Detailed mechanistic studies focus on transcription factor interactions with chromatin, particularly positioned nucleosomes.

Contact: 617-643-5428


Pedro Andreu-Perez, PhD

Hongxian Chen, MD, PhD 

Jun Dai, PhD

David E. Fisher, MD, PhD 

Adam Friedman, MD, PhD

Jessica Fuller

Rizwan  Haq, MD PhD 

Leeza Hargreaves 

Jennifer Hsiao 

Vivien Igras

Akinori Kawakami, MD, PhD

Daniel Kim 

Ju Hee Lee, MD, PhD 

Jue Judy Liu 

Jennifer Lo 

Ryo Murakami, PhD 

Katey Robinson 

Elisabeth Roider, MD 


Whitney Silkworth

Thanh Nga Tran, MD, PhD 

Christina Weng 

Chong Hyun Won, MD PhD

Ying Qi Zhang





Full Bibliography for David E. Fisher, MD PhDView my most recent publications at Pub MedOriginal Articles
1.    Fisher DE, Amend JF, Strumeyer DH.   Anserine and carnosine in chicks, rat pups, and ducklings:  comparative ontogenetic observations.   Comp Biochem Physiol  1977; 56:367-370.

2.    Fisher DE, Amend JF, Strumeyer, DH, Fisher H.   A role for carnosine and anserine in histamine metabolism of the traumatized rat.  Proc Soc Exp Biol Med 1978; 158:402-405.

3.    Barbaro D, Fisher DE, Strumeyer DH, Fisher H.  Developmental changes and dietary histidine manipulation:  effect on rat olfactory bulb and leg muscle components.  J Nutr 1978; 108:1348-54.

4.    Fisher DE, Connor GE, Reeves WH, Blobel G, Kunkel HG.   Synthesis and assembly of human small nuclear ribonucleoproteins generated by cell-free translation.  Proc Natl Acad Sci 1983; 80:6356-60.

5.    Bigler RD, Fisher DE, Wang CY, Rinnooy Kan EA, Kunkel HG.  Idiotype-like molecules on cells of a human T cell leukemia.  J Exp Med 1983; 158:1000-05.

6.    Fisher DE, Reeves, WH, Connor GE, Blobel G, Kunkel HG.  Pulse labeling of small nuclear ribonucleoproteins in vivo reveals distinct patterns of antigen recognition by human autoimmune antibodies.  Proc Natl Acad Sci 1984; 81:3185-9.

7.    Posnett DN, Bigler RD, Bushkin Y, Fisher DE, Chiorazzi N, Wang CY, Kunkel HG.   T cell anti-idiotypic antibodies reveal differences between two human leukemias.   J Exp Med 1984; 160:494-505.

8.    Reeves WH, Fisher DE, Lahita RG, Kunkel HG.   Autoimmune sera reactive with Sm antigen contain high levels of RNP-like antibodies.   J Clin Invest 1985; 75:580-7.

9.    Fisher DE, Conner GE, Reeves WH, Wisniewolski R, Blobel G.   Small nuclear ribonucleoprotein assembly in vivo: demonstration of a 6S RNA-free core precursor and posttranslational modification.   Cell 1985; 42:751-8.

10.    Fisher DE, Reeves WH, Wisniewolski R, Lahita RG, Chiorazzi N.  Temporal shifts from Sm to RNP reactivity in systemic lupus erythematosus.   Arth Rheum 1985; 28:1348-55.

11.    Reeves WH, Fisher DE, Wisniewolski R, Gottlieb AB, Chiorazzi N. Psoriasis and Raynaud's phenomenon associated with autoantibodies to U1 and U2 small nuclear ribonucleoproteins.   N Engl J Med 1986; 315:105-11.

12.    Fisher DE.  Phenytoin, leukopenia, and remission of exzema.  Annals of Int  Med  1987; 107:263-4.

13.    Fisher DE, Jacobson J Ault K, Harris N.   Diffuse large cell lymphoma with discordant bone marrow histology: clinical features and biological implications.  Cancer  1989; 64:1879-87.

14.    Berde CB, Sethna NF, Fisher DE, Kahn CH, Chandler P, Grier HE.  Celiac plexus blockade for a 3 year old boy with hepatoblastoma and refractory pain.   Pediatrics  1990; 86:779-781.

15.    Fisher DE, Carr CS, Parent L, Sharp PA.  TFEB has DNA-binding and oligomerization properties of a unique helix-loop-helix/leucine zipper family.  Genes & Dev  1991; 5:2342-2352.

16.    Fisher DE, Parent L, Sharp PA.  Myc/Max and other basic/helix-loop-helix/leucine zipper proteins bend DNA towards the minor groove.  Proc Natl Acad Sci  1992; 89:11779-11783.

17.    Fisher DE, Parent L, Sharp PA.  High affinity DNA binding Myc analogs: recognition by anhelixCell

18.    Fisher DE, Schnitt S, Christian, R, Harris J, Henderson IC.   Recurrent  ductal carcinoma in situ of the breast after mastectomy.   Cancer  1993; 71:3025-3028.

19.    Hemesath, T. J., Steingrimmson, E., McGill, G., Vaught J, Hodgkinson, C.A., Arnheiter, H., Copeland, N.G., Jenkins, N.A., and Fisher DE.  Microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family.  Genes and Development  1994; 8:2770-80.

20.    Lowe, S., Bodis, S., McClatchey, A., Remington, L., Ruley, H.E., Fisher, .E., Housman, D.E. & Jacks, T.  p53 status and the efficacy of cancer therapy in vivo.  Science   1994; 266:807-10.

21.    Parvin, J., McCormick, R., Sharp, P.A., & Fisher, D.E.  Prebending of a promoter sequence enhances affinity for the TATA binding factor.  Nature  1995; 373:724-727.

22.    Steingrimmson, E, Sawadogo, M, Gilbert, DJ, Zervos, AS, Brent, R,Blanar, MA, Fisher DE, Copeland, NG, and Jenkins, NA.  Murine chromosomal location of five b-HLH-ZIP transcription factor genes.  Genomics  1995; 28:179-83.

23.    Bodis, S., Siziopikou, K., Schnitt, S., Harris, J. & Fisher, D.E.  Extensive apoptosis in intraductal carcinoma of the breast.  Cancer  1996; 77:1831-35.

24.    Steingrimsson, E., Nii, A., McCormick, R., Fisher, D.E., Ferre-D'Amare, A.R., Russell, L.B., Burley, S.K., Ward, J.M., Jenkins, N.A., and Copeland, N.G.  The semidominant Mib mutation identifies a role for the HLH domain in DNA binding separate from its role in protein dimerization.  EMBO J.  1996; 15:6280-89.

25.    McCormick, R.J. & Fisher, D.E.  The leucine zipper may induce electrophoretic mobility anomalies without DNA bending.  Proc Natl Acad Sci  1996; 93:14434-39.

26.    McGill, G.C., Bates, R., Savage, R. & Fisher, D.E.  Transformation selective apoptosis in fibroblasts deprived of adhesion.   J. Cell Biol.  1997; 138:901-11.

27.    Westphal, C.H., Schmaltz, C., Rowan, S., Elson, A., Fisher, D.E., and Leder, P.  Genetic interactions between atm and p53 influence cellular proliferation and irradiation-induced cell cycle checkpoints.  Cancer Research 1997; 57:1664-67.

28.    Westphal, C.H., Rowan, S., Schmaltz, C. Elson, A., Fisher, D.E., and Leder, P.  atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity.  Nature Genetics 1997; 16:397-401.

29.    Bodis, S. & Fisher, D.E.  Highly conserved asparagine in the basic domain of Myc is dispensable for DNA binding, transformation, and apoptosis.  Biochem. Mol. Medicine  1997; 60:102-7.

30.    Hemesath, T.J., Price, E.R., Takemoto, C., Badalian, T., and Fisher, D.E.  MAPK links the transcription factor Microphthalmia to c-Kit signaling in melanocytes.  Nature 1998; 391:298-301.

31.    Weilbaecher, K, Hershey, C., Takemoto, C., Tashjian, A.H., and Fisher, D.E.  Age-resolving osteopetrosis: a rat model implicating Microphthalmia and the related transcription factor TFE3.  J. Exp. Med. 1998; 187:775-85.

32.    Schmaltz, C., Harrigan, P. & Fisher, D.E. Regulation of proliferation/survival decisions during tumor cell hypoxia.  Mol. Cell. Biol.  1998; 18:2845-54.            
33.    Aberdam, E., Bertolotto, C., Sviderskaya, E.V., de Thillot, V., Hemesath, T.J., Fisher, D.E., Bennett, D.C., Ortonne, J.-P., & Ballotti, R.  Involvement of Microphthalmia in the Inhibition of Melanocyte Lineage Differentiation and of Melanogenesis by Agouti Signal Protein.  J. Biol. Chem.  1998; 273: 19560-19565.

34.    Price, E.R., Ding, H.-F., Badalian, T., Bhattacharya, S., Takemoto, C., Hemesath, T., Yao, T.- P., & Fisher, D.E.  Phosphorylation of Microphthalmia links c-Kit signaling to the transcriptional coactivator p300/CBP.   J. Biol. Chem.  1998; 273(29), 17983-17986.

35.    Bertolotto, C., Abbe, P., Hemesath, T.J., Bille, K., Fisher, D.E., Ortonne, P. & Ballotti, R. Mi gene product as a signal transducer in cAMP-induced differentiation of melanocytes.  J. Cell Biol.  1998; 142: 827-35.

36.    Ding, H.-F., McGill, G.C., Rowan, S., Schmaltz, C., Shimamura, A., & Fisher, D.E.  Transformation-dependent regulation of caspase activation by p53 protein in a cell free system.  J. Biol. Chem.  1998; 273: 28,378-83.

37.    Price, E.R., Horstmann, M.R., Wells, A., Weilbaecher, K.N., Takemoto, C., Landis, M.W., & Fisher, D.E.  MSH signaling regulates expression of Microphthalmia, a gene deficient in Waardenburg Syndrome.  J. Biol. Chem. 1998; 273: 33,042-47.

38.    Hardenbergh, P., Hahnfeldt, P., Hlatke, L., Takemoto, C., Shimamura, A., McGill, G.C., Fung, C.Y., Bodis, S., & Fisher, D.E.  Distinct mathematical behavior of apoptotic vs. non-apoptotic tumor cell death.  Int. J. Rad. Oncol. Biol. Phys.   1999; 43: 601-05.

39.    King, R., Weilbaecher, K.N., McGill, G., Cooley, E., Mihm, M., & Fisher, D.E,  Microphthalmia transcription factor: a sensitive and specific melanocyte marker for melanoma diagnosis. Am J Pathol. 1999; 155(3):731-8.

40.    Arbiser, J.L., Raab, G., Rohan, R.M., Paul, S., Hirschi, K., Flynn, E., Price, R., Fisher, D.E., Cohen, C,, & Klagsbrun.  Isolation of Mouse Stromal cells associated with a human tumor using differential diphtheria toxin sensitivity. Am J Pathol. 1999; 155(3):723-9.

41.    Takeda, K., Takemoto, C., Kobayashi, I., Watanabe, A., Nobukuni, Y., Fisher, D.E., & Tachibana, M.  Perturbation of MITF phosphorylation is a potential cause of Waardenburg Syndrome type 2. Human Mol. Genetics  2000; 9:125-132.

42.    Wu, M., Hemesath, T., Takemoto, C.M., Horstmann, M.A., Wells, A.G., Price, R., Fisher, D.Z., & Fisher, D.E.  c-Kit triggers dual phosphorylations which couple activation and degradation of the essential melanocyte factor Mi.  Genes & Development 2000; 14:301-12.

43.    Ding, H.-F., McGill, G., Juo, P., Zhu, H., Blenis, J., Yuan, J., Fisher, D.E.  Essential Role for Caspase-8 in Transcription-Independent Apoptosis Triggered by p53.  J. Biol. Chem.  2000; 275:38905-38911.

44.    Granter, S.R., Weilbaecher, K.N., Quigley, C., Fletcher, C.D.M., & Fisher, D.E. Clear Cell Sarcoma (Melanoma of soft parts) and immunoreactivity for Microphthalmia Transcription Factor:  further evidence for melanocytic differentiation.  Modern Pathology. 2001; 14(1):6-9.

45.    Granter, S.R., Weilbaecher, K.N., Quigley, C., Fletcher, C.D.M., & Fisher, D.E. Microphthalmia Transcription Factor is not a sensitive marker for the diagnosis of Desmoplastic Melanoma and Spindle Cell (Non-Desmoplastic) Melanoma. Am J Dermatopathol.  2001; 23(3):185-9.

46.    King, R., Googe, P.B., Weilbaecher, K.N., Mihm, M.C., and Fisher, D.E. Microphthalmia transcription factor expression in cutaneous benign and malignant melanocytic and non-melanocytic tumors. Am J Surg Pathol. 2001; 25:51-7.

47.    Granter, S.R., Weilbaecher, K.N., Quigley, C., & Fisher, D.E.   Role for Microphthalmia transcription factor (Mitf) in the diagnosis of metastatic malignant melanoma.  Applied Immunohist. and Mol. Morphol. 2002; 10(1):47-51.

48.    Bates, R.C., Edwards, N.S., Burns, G.F., and Fisher, D.E. A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells.  Cancer Res. 2001; 61(13):5275-83

49.    Jungbluth A.A., King, R., Fisher, D.E., Iversen, K., Coplan, K., Kolb, D., Williamson, B., Chen, Y., Stockert, E., Old, L.J., Busam, K.J.  . Immunohistochemical and RT-PCR Expression Analysis of Tyrosinase and Microphthalmia Transcription Factor (Mitf) in Angiomyolipomas.    Applied Immunohist. & Mol. Morphology  2001; 9; 29.

50.    Motyckova, G., K. N. Weilbaecher, M. Horstmann, D. J. Rieman, D. Z. Fisher, and D. E. Fisher . Linking osteopetrosis and pycnodysostosis: Regulation of cathepsin K expression by the microphthalmia transcription factor family. Proceedings of the National Academy of Sciences 2001; 98: 5798-5803

51.    Dorvault CC, Weilbaecher KN, Yee H, Fisher DE, Chiriboga LA, Xu Y, Chhieng DC.  Microphthalmia transcription factor: a sensitive and specific marker for malignant melanoma in cytologic specimens.  Cancer 2001 Oct 25;93(5):337-43

52.    Weilbaecher, K.N., Motyckova, G., Huber, W.E., Takemoto, C. E., Hemesath, T.J., Xu, Y., Hershey, C.L., Dowland, N.R., Wells, A.G., and Fisher, D.E.  Linkage of M-CSF signaling to Mitf, TFE3, and the osteoclast defect in Mitfmi/mi mice.  Molecular Cell   2001; 8(4):749-58.

53.    Pruschy, M., Rocha, S., Zaugg, Tenzer, Hess, Fisher, D.E., Glanzmann, C., Bodis S. Key targets for the execution of radiation induced tumor cell apoptosis: The role of p53 and caspases.  Int. J. Radiation Oncol. Biol. & Physics.  2001; 1;49(2):561-7.

54.    B.Z. Lin, L. Babiarz, F. Liebel, E. R. Price, D. E. Fisher, G. J. Gendimenico, and M. Seiberg. Modulation of MITF Transcription alters skin pigmentation.  J. Invest. Dermatol.  2002;119(6):1330-40.

55.    R King, A Peterson, K Peterson, MC Mihm Jr, DE Fisher, PB Googe.  Microphthalmia transcription factor expression in cutaneous mast cell disease.  Am J Dermatopathol. 2002; 24(3):282-4.

56.    Arbiser, J.L., Yeung, R., Weiss, S.W., Arbiser, Z.K., Amin, M.B., Cohen, C., Frank, D., Mahajan, S., Herron, G.S., Yang, J., Onda, H., Zhang, H.B., Bai, X., Uhlmann, E., Loehr, A., Northrup, H., Au, P., Davis, I., Fisher, D.E., & Gutmann, D.H.  The generation and characterization of a cell line derived from a sporadic renal angiomyolipoma:  use of telomerase to obtain stable populations of cells from benign neoplasms.  Am J Pathol. 2001; 159(2):483-91.

57.    Morii, E., Ogihara, H., Oboki, K., Kataoka, T.R.,  Maeyama, K., Fisher, D.E., Lamoreux, M.L., and Kitamura. Y. Effect of large deletion of basic domain of mi transcription factor (MITF) on differentiation of mast cells.  Blood. 2001; 15;98(8):2577-9.

58.    Du, J. and Fisher, David E.   Identification of Aim-1 as the underwhite mutant and its transcriptional regulation by MITF. J Biol Chem. 2002; 277:402-6.

59.    Selzer, E., Wacheck, V., Lucas, T., Heere-Ress, E.,Wu, M. Schlegel, S, Valent, P., Wrba, F.,  Pehamberger,  H., Fisher, D.E., and Jansen, B.  The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma. Cancer Research, 2002; 62(7):2098-103..

60.    Takemoto, C.M., Yoon, J., and Fisher, D.E.  The identification and characterization of a novel mast cell isoform of the Microphthalmia-associated transcription factor (Mitf).  J Biol Chem. 2002;16;277(33):30244-52.

61.    McGill, G., Horstmann, M., Widlund, H., Du, j., Motyckova, G., Nishimura, E., Lin, Y., Ramaswamy, S., Avery, W., Ding, H., Korsmeyer, S.J., Golub, T., &  Fisher, D.E.  Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability.  Cell  2002; 109:707-718.

62.    Sheffield, M.V., Yee, H., Dorvault, C.C., Weilbaecher, K.N., Eltoum, I.A., Siegal, G.P., Fisher, D.E., & Chhieng, D.C.  Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations.  Am J Clin Pathol. 2002;118(6):930-6.

63.    Wang, Y., Cui, H., Schroering, A., Ding, J.L., Lane, W.S., McGill, G., Fisher, D.E. & Ding, H.  NF-B2 p100 is a pro-apoptotic protein with anti-oncogenic function.  Nat Cell Biol. 2002; 4(11):888-93.

64.    Widlund, H.R., Horstmann, M.A., Price, E.R., Cui, J., Lessnick, S.L., Wu, M., He, X., and  Fisher, D.E.  -Catenin-induced melanoma growth requires the downstream target MITF.  J Cell Biol. 2002; 16;158(6):1079-87.

65.    Baksh S, Widlund HR, Frazer-Abel AA, Du J, Fosmire S, Fisher DE, DeCaprio JA, Modiano JF and Burakoff SB.  NFATc2-mediated repression of cyclin dependent kinase 4 transcription.  Molecular Cell. 2002;10(5):1071-81.

66.    So H, Rho J, Jeong D, Park R, Fisher DE, Ostrowski MC, Choi Y, Kim N.  Microphthalmia transcription factor and PU.1 synergistically induce the leukocyte receptor OSCAR gene expression. J Biol Chem. 2003 Jun 27;278(26):24209-16

67.    Du, J, Miller, AJ, Widlund, HR, Horstmann, MA, Ramaswamy, S, and Fisher, DE.  MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma.   Am J Pathol. 2003 Jul;163(1):333-43.

68.    Davis, IJ, Bae-Li, H., Arroyo, JD, Vargas, SO, Yeh, YA, Motyckova, G., Valencia, P, Perez-Atayde, AR, Argani, P, Ladanyi, M, Fletcher, JA, and Fisher, DE. Cloning of a Novel Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation.  Proc. Natl. Acad. Sci.   2003 13;100(10):6051-6.

69.    Chen, D, Xu, W, Bales, E, Colmenares, C, Conacci-Sorrell, M, Eling, D, Ishii, S, Stavnezer, E. Campisi, J, Fisher, DE, Ben-Ze'ev,  A, and Medrano, EE.  SKI activates Wnt/-catenin signaling in human melanoma.  Cancer Res.  2003 Oct 15;63(20):6626-34.

70.    Huber, WE, Price, ER, Widlund, HR, Du, J, Davis, IJ, Wegner, M, and Fisher, DE.  A tissue restricted cAMP transcriptional response: SOX10 modulates MSH-triggered expression of MITF in melanocytes.  J Biol Chem  2003 Nov 14;278(46):45224-30

71.    Miller, AJ, Du, J, Rowan, S, Hershey, CL, Widlund, HR, and Fisher, DE.    Transcriptional regulation of the melanoma prognostic marker Melastatin (TRPM1) by MITF in melanocytes and melanoma.  Cancer Res. 2004 Jan 15;64(2):509-16

72.    Vetrini, F., Auricchio A., Du, J., Angeletti, B., Fisher, D.E., Ballabio, A., and Marigo, V. The microphthalmia transcription factor (Mitf) controls expression of the ocular albinism type 1 gene: a link between melanin synthesis and melanosome biogenesis.  Mol Cell Biol.  2004, 24(15):6550-9

73.    Rowan S, Chen CM, Young TL, Fisher DE, Cepko CL.  Transdifferentiation of the retina into pigmented cells in ocular retardation mice defines a new function of the homeodomain gene Chx10.  Development. 2004 Oct;131(20):5139-52.

74.    Du, J., Widlund, H.R., Horstmann, M.A., Ramaswamy, S., Ross, K., Huber, W.E., Nishimura, E.K., Golub, T.R., and Fisher, D.E.  Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 2004 Dec;6(6):565-76.

75.    Bentires-Alj, M, Paez, GJ, David, FS, Halmos, B, Naoki, K, Maris, JM, Richardson, A, Bardelli, A, Sugarbaker, DJ, Richards, WG, Du, J, Girard, L, Minna, JD, Loh, ML, Fisher, DE, Velculescu, VE, Vogelstein, B, Meyerson, M, Sellers, WR, and Neel, BG.  Mutations of the Noonan syndrome-associated Shp2/PTPN11 gene in some human solid tumors and adult AML.  Cancer Res.  2004 Dec 15;64(24):8816-20.

76.    Miller AJ, Levy C, Davis IJ, Razin E, Fisher DE. SUMOylation of MITF and its related family members TFE3 and TFEB. J Biol Chem. 2005 Jan 7;280(1):146-55.

77.    Hershey, C. and Fisher, D.E.  Genomic analysis of the Microphthalmia Locus and identification of the MITF-J/Mitf-J isoform.  Gene 2005 Feb 28;347(1):73-82.

78.    Patton, E., Widlund, HR, Kutok, JR, Kopani, KR, Amatruda JF, Murphey, RD, Berghmans, S, Mayhall, EA, Aster, JC, Granter, SR, Look, AT, Lee, C, Fisher, DE, and Zon L.  BRAF mutations are sufficient to promote nevus formation, and cooperate with p53 in the genesis of melanoma. Current Biology 2005 Feb 8;15(3):249-54.

79.    Nishimura, EK, Granter, S, and Fisher, DE.  Mechanisms of hair graying: incomplete self-maintenance of melanocyte stem cells in the niche. Science 2005 Feb 4;307(5710):720-4.

80.    Argani P, Lae M, Hutchinson B, Reuter VE, Collins MH, Perentesis J, Tomaszewski JE, Brooks JS, Acs G, Bridge JA, Vargas SO, Davis IJ, Fisher DE, Ladanyi M.  Renal Carcinomas With the t(6;11)(p21;q12): Clinicopathologic Features and Demonstration of the Specific Alpha-TFEB Gene Fusion by Immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol. 2005 Feb;29(2):230-240.

81.    Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.  Nature. 2005 Jul 7;436(7047):117-22.

82.    Mukohara T, Civiello G, Davis I, Taffaro ML, Christensen J, Fisher DE, Johnson BE, and Janni PA.  Inhibition of the Met receptor in mesothelioma,  Clinical Cancer Research, 2005 Nov 15;11(22):8122-30

83.    Kim K, Kim JH, Lee J, Jin HM, Lee SH, Fisher DE, Kook H, Kim KK, Choi Y, and  Kim K.  NFATc1 induces OSCAR gene expression during TRANCE-mediated osteoclastogenesis. Journal of Biological Chemistry. 2005 Oct 21;280(42):35209-16

84.    McGill GC, Haq R, Nishimura EK, and Fisher DE.  c-met expression is regulated by Mitf in the melanocyte lineage.  J. Biol. Chem. 2006 Apr 14;281(15):10365-73.

85.    Davis IJ, Kim JJ, Ozsolak F, Widlund HR, Rozenblatt-Rosen O, Granter SR, Du J, Fletcher JA, Denny CT, Lessnick SL, Linehan WM, Kung AL, and Fisher DE. Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers.  Cancer Cell, 2006 Jun;9(6):473-84.

86.    D’Orazio JA, Nobuhisa T, Cui R, Arya M, Spry M, Wakamatsu K, Igras V, Kunisada T, Granter SR, Nishimura EK, Ito S, Fisher DE. Critical role for MC1R in UV tanning: molecular mimicking and skin protection. Nature, 2006 Sep 21;443(7109):340-4.

87.    Tsuda M, Davis IJ, Argani P, Shukla N, McGill GC, Nagai M, Saito T, Lae M, Fisher DE, Ladanyi M. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition.  Cancer Research, 2007  67(3):919-29

88.    Ozsolak F, Song JS, Liu XS, and Fisher DE. Global chromatin structure mapping of human promoters. Nature Biotechnology, 2007   25(2):244-8

89.    Chang EJ, Kim HJ, Ha J, Kim HJ, Ryu J, Park KH, Kim UH, Lee ZH, Kim HM, Fisher DE, Kim HH.  Hyaluronan inhibits osteoclast differentiation via Toll-like receptor 4. J Cell Sci., 2007  1;120(Pt 1):166-76

90.    Cui R, Widlund HR, Feige E , Lin JY, Wilensky DL, Igras VE, D’Orazio J, Fung CY, Schanbacher CF, Granter SR, and Fisher DE. The suntan response: p53 transactivation of POMC/MSH and its mimicking in skin diseases.  Cell 2007 9;128(5):853-64

91.    Lim SD, Stallcup W, Lefkove B, Govindarajan B, Au KS, Northrup H, Lang D, Fisher DE, Patel A, Amin MB, Arbiser JL. Expression of the neural stem cell markers NG2 and L1 in human angiomyolipoma: are angiomyolipomas neoplasms of stem cells?  Mol Med. 2007  Mar-Apr;13(3-4):160-5

92.    Widlund HR, Fisher DE, Potent p53-independent tumor suppressor activity of ARF in melanoma-genesis.  Pigment Cell Research 2007 Oct;20(5):339-40

93.    Sato-Jin K, Nishimura EK, Akasaka E, Huber W, Nakano H, Miller A, Du J, Wu M, Hanada K, Sawamura D, Fisher DE, Imokawa G. Epistatic connections between microphthalmia-associated transcription factor and endothelin signaling in Waardenburg syndrome and other pigmentary disorders.  FASEB J 2008  Apr;22(4):1155-68.

94.    Kawakami A, Sakane F, Imai SI, Yasuda S, Kai M, Kanoh H, Jin HY, Hirosaki K, Yamashita T, Fisher DE, Jimbow K. Rab7 Regulates Maturation of Melanosomal Matrix Protein gp100/Pmel17/Silv.  J Invest Dermatol. 2008  Jan;128(1):143-50

95.    Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE.  Major response to imatirib mesylate in KIT-mutated melanoma.  J Clin Oncol. 2008 Apr 20;26(12):2046-51.

96.    X Jiang, J Zhou, NK. Yuen, CL. Corless, MC. Heinrich, JA. Fletcher, HR Widlund, DE. Fisher, and FS Hodi  Imatinib Targeting of KIT-mutant Oncoprotein in Melanoma.  Clin Cancer Res. 2008 Dec 1;14(23):7726-32

97.    S Yokoyama, E Feige, LL. Poling, C Levy, HR Widlund, M Khaled, AL Kung, and DE Fisher.  Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. Pigment Cell Melanoma Res. 2008 21; 457–463

98.    Ozsolak F, Poling LL, Wang Z, Liu, H, Liu XS, Roeder, RG, Zhang X, Song JS, and Fisher DE. Chromatin Structure Analyses Identify miRNA Promoters. Genes Dev. 2008 Nov 15;22(22):3172-83.  

99.    Zhao X, Graves C, Ames SJ, Fisher DE, Spanjaard RA.   Mechanism of regulation and suppression of melanoma invasiveness by novel retinoic acid receptor-gamma target gene carbohydrate sulfotransferase Cancer Res. 2009 Jun 15;69(12):5218-25.

100.    Scott, KL, Kabbarah, O, Liang, M-C, Ivanova, E., Anagnostou, V., Wu, J., Dhakal S., Wu, M, Chen S, Feinberg T., Huang J, Saci A, Widlund HR, Fisher DE, Xiao Y, Rimm DL, Protopopov, A, Wong K-K, and Chin L. GOLPH3 modulates mTOR signaling and rapamycin sensitivity in cancer.  Nature 2009 Jun 25;459(7250):1085-90.  

101.    Davis IJ, McFadden A, Yixiang Z, Coxon A, Burgess T, Wagner A , and Fisher DE. Identification of the Receptor Tyrosine Kinase cMet and Its Ligand, Hepatocyte Growth Factor, as Therapeutic Targets in Clear Cell Sarcoma. Cancer Research 2010 Jan 15; 70(2)

102.    Nishimura EK, Suzuki M, Igras V, Du J, Lonning S, Miyachi Y, Roes J, Beermann F, Fisher DE. Key role for transforming growth factor β in melanocyte stem cell maintenance. Cell Stem Cell 2010 Feb 5;6(2):130-40.

103.    Berger MF, Levin JZ, Vijayendran K, Sivachenko A, Adiconis X, Maguire J, Johnson LA, Robinson J, Verhaak RG, Sougnez C, Onofrio RC, Ziaugra L, Cibulskis K, Laine E, Barretina J, Winckler W, Fisher DE, Getz G, Meyerson M, Jaffe DB, Gabriel SB, Lander ES, Dummer R, Gnirke A, Nusbaum C, Garraway LA. Integrative analysis of the melanoma transcriptome. Genome Res. 2010 Apr;20(4):413-27.

104.    Jané-Valbuena J, Widlund HR, Perner S, Johnson LA, Dibner AC, Lin WM, Baker AC, Nazarian RM, Vijayendran KG, Sellers WR, Hahn WC, Duncan LM, Rubin MA, Fisher DE, Garraway LA. An Oncogenic Role for ETV1 in Melanoma. Cancer Research 2010 Mar 1;70(5):2075-84. Epub 2010 Feb 16

105.    Levy C , Khaled M, Robinson KC, Veguilla RA, Chen PH, Yokoyama S, Makino E, Lu J, Larue L, Beermann F, Chin L, Bosenberg M, Song JS, Fisher DE. Lineage specific transcriptional regulation of DICER by MITF in melanocytes. Cell. 2010 Jun 11;141(6):994-1005.

106.    Gordon P, Fisher DE. Role for the pro-apoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT dependent gastrointestinal stromal tumor cell line.
J Biol Chem. 2010 May 7;285(19):14109-14.

107.    Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H, Wargo JA. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Research. 2010 Jul 1;70(13):5213-9.  

108.    Khaled M, Levy C, Fisher DE. Control of melanocyte differentiation by a MITF-PDE4d3 homeostatic circuit. Genes and Dev. 2010 Oct 15;24(20):2276-81.

109.    Kim DS, Park SH, Jeong YM, Kwon S, Miller AJ, Fisher DE, Park KC.
Sphingosine-1-phosphate decreases melanin synthesis via microphthalmia-associated transcription factor phosphorylation through the S1P3 receptor subtype..
J. Pharmacy and Pharmacology.  2011 63: 409–416

110.    Levy, C,  Khaled, M., Iliopoulos, D., Janas, M., Schubert, S., Pinner,S, Chen, P-H, Li, S., Fletcher, A., Yokoyama, S., Scott, K.L., Garraway,L.A., Song,J.S., Granter, S.R., Turley, S.J., Fisher, D.E., and Novina, C.D. Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Molecular Cell 2010.
Dec 10;40(5):841-9

Reviews and Book Chapters:
111.    Fisher DE.  Positive and negative transacting factors and their modification.  In Negative Regulators of Hematopoeisis, ed. M. Guigon. (Collogne INSERM/John Libbey Eurotext) 1993

112.    Fisher, D.E.  Apoptosis in cancer therapy: crossing the threshold.  Cell 1994; 778:539-542.

113.    Takemoto, C. & Fisher, D.E.  Structural constraints for DNA recognition by Myc and other b-HLH-ZIP proteins: design of oncoprotein analogs.  Gene Expression 1995; 4:311-17.

114.    Lowe, S.W, Bodis, S., Bardeesy, N, McClatchey, A, Remington, L, Ruley, H.E., Fisher, D.E., Jacks, T., Pelletier, J. and Housman, D.E. Apoptosis and the Prognostic Significance of p53 Mutation.  Cold Spring Harbor Sym. Quant. Bio. 1994; 59:419-26.

115.    Fung, C.Y. & Fisher D.E.  Apoptosis and p53:  critical determinants of outcome in cancer radiation and chemotherapy.  J. Clin. Oncol. 1995; 13:808-811.

116.    Shimamura, A. and Fisher, D.E.  p53 in Life and Death.  Clinical Cancer Research.  1996; 2:435-440.

117.    Hoeppner, D, Hengartner, M. O, Fisher, D. E. Programmed cell death:  from development to disease. BBA Reviews on Cancer 1996; 1242:217-20.

118.    Fisher, D.E.  Apoptosis, Chemotherapy, and Aging. Chapter in Comprehensive Geriatric Oncology, L. Balducci, G.H. Lyman, W.B. Ershler Eds., pp.237-245, Harwood Academic Publishers, Amsterdam. 1998

119.    Rowan, S. & Fisher, D.E.  Apoptosis in cancer therapy.  Leukemia.  1997; 11:457-65.

120.    McGill, G.C. & Fisher, D.E.  Apoptosis in tumorigenesis and cancer therapy.  Frontiers in Bioscience.  1997; 2: 353-79.

121.    Goding, C. & Fisher, D.E.  Melanocyte growth and development:  meeting review.  Cell Growth & Differentiation 1997; 8:935-40.

122.    McGill, G. & Fisher, D.E.  DNA bending and the curious case of Fos/Jun. Chemistry and Biology 1998; 5:29-38

123.    Fisher, D.E. Microphthalmia transcription factor in melanocyte development.  Accomplishments in Cancer Research 1997- General Motors Cancer Research Foundation Symposium. Eds. Wells, S.A. & Sharp, P.A. pp 113-119, Lippincott Williams & Wilkins 1998

124.    Bodis, S., Pruschy, M., Glanzmann, C., Krek, W., Lowe, S.W., & Fisher D.E.  p53 status and radiosensitivity. "Progress in Radio-Oncology VI" H.D. Kogelnik & F. Sedlmayer eds.  Monduzzi Editore, Bologna  1998

125.    Ding, H.-F & Fisher, D.E.  Mechanisms of p53-mediated apoptosis. Critical Reviews in Oncogenesis. 1998; 9: 83-98.

126.    Fisher, D.E.  Apoptosis, Chemotherapy, and Aging. Chapter in Comprehensive Geriatric Oncology, L. Balducci, G.H. Lyman, W.B. Ershler Eds., Harwood Academic Publishers, Amsterdam.  Edition 2. 1998; Pg. 237- 245

127.    Wu. M. & Ding, H.-F., Fisher, D.E.  Apoptosis:  Molecular Mechanisms. in Encyclopedia  of Life Sciences, Nature Publishing Group, Macmillan Press. London, HYPERLINK (1999)

128.    Sellers, W.R. and Fisher, D.E.  Apoptosis and Cancer Drug Targeting.  J. Clin. Invest. 1999; 104:1655-61.

129.    McGill, G. & Fisher, D.E.  p53 and apoptosis: a double edged sword.  J. Clin. Invest.  1999; 104: 223-5.

130.    Fisher, D.E. Turning p53 on or off:  either way may treat cancer.  Drug Resistance Updates 2000; 3:77-79.

131.    Fisher, D.E. Microphthalmia: a signal responsive transcriptional regulator in development.  Pigment Cell Research 2000 S8: 145-149.

132.    Fisher, D.E.  The p53 tumor suppressor:  critical regulator of life and death in cancer.  Apoptosis. 2001; 6: 7-15.

133.    Price, E.R. & Fisher, D.E. Sensorineural deafness and pigmentation genes: melanocytes and the Mitf transcriptional network. Neuron 2001; 30(1):15-8.

134.    Ding, H.-F. & Fisher, D.E.   p53 and regulation of apoptosis in cancer therapy.  J. Pediatric Hematology/Oncology. 2001; Mar-Apr;23(3):185-8.

135.    Du, J. and Fisher, D.E.  Apoptosis: machinery of cell death in development and cancer.  Chapter in Tumor Suppressor Genes in Cancer Therapy, Totowa, NJ, Humana Press (2001)

136.    Skolnik, J.M. & Fisher, D.E.  Tumor Suppressor Genes, in Encyclopedia  of Life Sciences, Nature Publishing Group, Macmillan Press. London.  HYPERLINK .(2001)

137.    Fisher, D.E.  Pathways of apoptosis and the modulation of cell death in cancer.  Hematology/Oncology Clinics of North America.  2001; 15 (5):  931-56.

138.    Kaplan, R. & Fisher, D.E.  p53, apoptosis, and cancer therapy. Chapter in Cell Cycle Checkpoints and Cancer,, Landes Bioscience, Georgetown, Texas, Edit. M. Blagosklonny (2002)

139.    Fisher, D.E.  Regulation of the Microphthalmia Transcription Factor.  in Mechanisms of Suntanning.  J.-P. Ortonne and R. Ballotti eds.  Martin Dunitz Pub., London. 2002.

140.    Motyckova, G. and Fisher, D.E. Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease.  Current Molecular Medicine 2002; 2(5) 407-21.

141.    Halaban R, Hebert DN & Fisher DE. Biology of Melanocytes. In: Freedberg IM, Wolff K, Austen KF, Goldsmith LA, Katz SI (eds)Fitzpatrick's Dermatology in General Medicine (2003) New York: McGraw-Hill p 127–148

142.    Fisher, D.E.  The Henry Kunkel legacy:  from the eyes of his last student.  Lupus.  2003;12(3):172-4

143.    Widlund, H.R. & Fisher, D.E.  Microphthalmia-associated transcription factor: a critical regulator of pigment cell development and survival.  Oncogene  2003,  22; 3035-41

144.    Ding, H.F, and Fisher, D. E. Induction of apoptosis in cancer: new therapeutic opportunities.  Annals of Medicine. 2002;34(6):451-69.

145.    Hershey, C, and Fisher, DE.  Mitf and Tfe3: Members of a b-HLH-ZIP Transcription Factor Family Essential for Osteoclast Development and Function.  Bone. 2004  34(4):689-96

146.    Erez Feige, Laura L. Poling and David E. Fisher.  MITF: critical regulator of the melanocyte lineage.  In Melanocyte Biology, V. Hearing editor, Humana Press (2005)

147.    Fisher DE. Ras and Raf in melanoma: oncogenes, signaling pathways, and drug targets.  ASCO Educational Book  2005  Cadmus

148.    Wagner AJ, and Fisher DE.  Melanocyte Signaling Pathways. Drug Discovery Today, Disease Mechanisms. 2005 ISSN1740-6765, pg179-183.

149.    Garraway LA, Weir BA, Zhao X, Widlund H, Beroukhim R, Berger A, Rimm D, Rubin MA, Fisher DE, Meyerson ML, Sellers WR. "Lineage Addiction" in Human Cancer: Lessons from Integrated Genomics” Cold Spring Harb Symp Quant Biol. 2005; 70:25-34.

150.    Fisher DE. Dissecting the melanoma enigma: learning from the details.  Commentary, Society for Melanoma Research Website at: .2005

151.    Chin L, Garraway LA, and Fisher DE.  Malignant Melanoma: Biology and Therapeutics in the Genome Era.  Genes & Development. 2006 Aug 15;20(16):2149-82.

152.    Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med. 2006 Sep;12(9):406-14.

153.    Fisher DE.  Lessons for melanoma from the biology of the melanocyte. The Melanoma Letter  2006  24(3);1

154.    Lin, J, Fisher DE.  Melanocyte biology and skin pigmentation.  Nature  2007 Feb 22;445(7130):843-50

155.    Davis IJ, Fisher DE, MiT transcription factor associated malignancies in man.  Cell Cycle 2007  May,6(14):1724-9

156.    Fisher JM, Fisher DE. From suntan to skin cancers: molecular pathways and prevention strategies.  Targeted Oncology. (2008) 3:41–44

157.    Haq R, Fisher DE. Pigmentation pathways and Microphthalmia-Associated Transcription Factor as new targets in melanoma.  Chapter from Melanoma: Translational Research and Emerging Therapies ed. Taylor & Francis, Inc S. Agarwal and V. Sondak. (2008) pgs. 99110

158.    Tran TN, J Schulman, and DE Fisher.  UV and pigmentation: molecular mechanisms and social controversies. Pigment Cell Melanoma Res. 2008  21; 509–516

159.    Osawa M, DE Fisher.  Multiple Roles of Notch Signaling in the Melanocyte Lineage: How a Single Signaling Produce Diverse Outcomes?  J Invest. Dermatology.  2008 Nov;128(11):2571-4

160.    Fisher DE, Hodi S. Adoptive transfer of antigen-specific CD4+ T Cells in the Treatment of Metastatic Melanoma. Nature Clinical Practice Oncology (2008) 5, 696-697"

161.    Robinson KC, Fisher DE. Specification and loss of melanocyte stem cells. Semin Cell Dev Biol. 2009 Feb;20(1):111-6. Epub 2008 Dec 13.

162.    Davis IJ, Perez-Atayde AR, Fisher DE. Nonrhabdomyosarcomas and Other Soft Tissue Tumors. Oncology of Infancy and Childhood.  2009  20; 783-828

163.    Schulman JM, Fisher DE. Indoor ultraviolet tanning and skin cancer: health risks and opportunities. Curr Opin Oncol. 2009 Mar; 21(2):144-9. Review.

164.    Yokoyama S, Salma N, Fisher DE. MITF pathway mutations in melanoma. Pigment Cell and Melanoma Research. 2009 Aug;22(4):376-7.

165.    Mitra D, Fisher DE.  Transcriptional regulation in melanoma. Hematol Oncol Clin North Am. 2009 Jun;23(3):447-65

166.    Park JM, Fisher DE. Testimony from the bedside: from Coley's toxins to targeted immunotherapy. Cancer Cell. 2010 Jul 13;18(1):9-10.

167.    Weinberg R, Fisher DE, Rich J. Dynamic and transient cancer stem cells nurture melanoma. Nat Med. 2010 Jul;16(7):758.

168.    Garibyan L, Fisher DE. How sunlight causes melanoma. Curr Oncol Rep. 2010 Sep;12(5):319-26.

169.    Weinstock MA, Fisher DE. Indoor ultraviolet tanning: what the data do and do not show regarding risk of melanoma and keratinocyte malignancies. J Natl Compr Canc Netw. 2010 Sep;8(8):867-73.

170.    Smruti J Vidwans;Keith T Flaherty;David E Fisher;Jay M Tenenbaum;Michael D
Travers;Jeff Shrager. Melanoma Reference Model. Melanoma Commons. 2010.

171.    Fisher DE, James WD. Indoor tanning -- science, behavior, and policy. N Engl J Med. 2010 Sep 2;363 (10):901-3.

172.    Liu J, Fisher DE. Lighting a path to pigmentation: Mechanisms of MITF induction by UV. Pigment Cell Melanoma Res. 2010 Dec;23(6):741-5.

173.    Ko J, Fisher DE. A New Era: Melanoma Genetics and Therapeutics. Journal of Pathology. 2011 Jan;223(2):242-51.

174.    Seo S, Fisher DE. Melanocyte photobiology, ultra violet radiation and melanoma. Giornal Ital. Dermat. 2010. 2010 Oct;145(5):603-11.

175.    Levy C, Fisher DE. Dual roles of lineage restricted transcription factors: the case of MITF in melanocytes. Transcription. 2011 Jan;2:1:19-22.

176.    Osawa M, Nishimura EK, Fisher DE. Profile: Shin-Ichi Nishikawa. Pigment Cell Melanoma Res. 2010. Oct; 23;683

177.    Skolnik, J, Fisher DE. Tumour Suppressor Genes. Encyclopedia of Life Sciences. 2010. In Press

178.    D’Orazio J, Fisher DE. Central Role for cAMP signaling in Pigmentation and UV resistance. Cell Cycle. 2010 Cell Cycle. 2011 Jan 1;10(1):8-9.

179.    Yokoyama S, Fisher DE. Transcriptional Regulation in Melanoma. Melanoma development – Molecular biology, genetics and clinical application. Springer. 2010 In Press

180.    Mitra, D, Robinson K, Fisher DE. Melanoma and Viagra: an unexpected connection. Pigment Cell Melanoma Res. 2010. Feb;24(1):16-8.

181.    Kim DS, Park SH, Jeong YM, Kwon SB, Miller AJ, Fisher DE, Park KC. Sphingosine-1-phosphate decreases melanin synthesis via microphthalmia-associated transcription factor phosphorylation through the S1P3 receptor subtype. J.Pharmacy and Pharmacology. 2011. Jun; 63: 409–416.

182.    Fisher DE. UV-tanning behavior: a problem that doesn't go away. Pigment Cell Melanoma Res. 2011 May 3

183.    Arbiser JL, Fisher DE. Fisetin: A Natural Fist against Melanoma? J Invest Dermatol. 2011 Jun;131(6):1187-9.

184.    Song J, Fisher DE. Nucleosome positioning in promoters: significance and open questions. Epigenomics: From Chromatin Biology to Therapeutics.
2011.In Press

185.    Flaherty K, Fisher DE. New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advances “New Strategies In…” 2011. In Press

186.    Haq, R, Fisher DE. Biology and clinical relevance of the MiT family of transcription factors in human cancer," J. Clin Oncol. 2011. In Press

Book Editor:
187.    Fisher, D.E. editor, Tumor Suppressor Genes in Cancer Therapy, Totowa, NJ, Humana Press. 2001 Feb-Apr; 6(1-2):7-15.  

188.    Fisher, D.E. co-editor, Nathan and Oski's Hematology of Infancy and Childhood. 7th ed. Philadelphia, PA, W B Saunders Co. 2009.

189.    Fisher, D.E. co-editor, Oncology of Infancy and Childhood.1st ed. Philadelphia, PA, Saunders Elsevier. 2009.

190.    Fisher, D.E. editor, Hematology/Oncology Clinics of North America, Philadelphia, PA, Saunders Elsevier. 2009. June; 23(3): 447-465.

191.    Fisher DE, Barnhill R, Hodi FS, Herlyn M, Merlino G, Medrano E, Bastian B, Landi TM, Sosman J. Melanoma from bench to bedside: meeting report from the 6th international melanoma congress. Pigment Cell and Melanoma Research 2010 Feb;23(1):14-26. Epub 2009 Dec 17.

192.    Garibyan L and Fisher DE.  Update on Melanoma Pathogenesis, for Fitzpatrick Textbook of Dermatology in Medicine.  2010. In Press

193.    Hawryluk E, Fisher DE. "Melanoma / Book 3". In Tech. 2011. In Press